231 related articles for article (PubMed ID: 30762219)
1. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Kizaki M; Takahashi N; Iriyama N; Okamoto S; Ono T; Usui N; Inokuchi K; Nakaseko C; Kurokawa M; Sumi M; Nakamura F; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Matsumura I; Naoe T;
Int J Hematol; 2019 Apr; 109(4):426-439. PubMed ID: 30762219
[TBL] [Abstract][Full Text] [Related]
2. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
Nakamae H; Fujisawa S; Ogura M; Uchida T; Onishi Y; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Ohashi K; Li L; Miyoshi M
Int J Hematol; 2017 Jun; 105(6):792-804. PubMed ID: 28341918
[TBL] [Abstract][Full Text] [Related]
4. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
Ren X; Qin Y; Huang X; Zuo L; Jiang Q
Ann Hematol; 2019 Jul; 98(7):1627-1640. PubMed ID: 31089794
[TBL] [Abstract][Full Text] [Related]
6. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
[TBL] [Abstract][Full Text] [Related]
7. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M
Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583
[TBL] [Abstract][Full Text] [Related]
12. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
13. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
Jain P; Kantarjian H; Sasaki K; Jabbour E; Dasarathula J; Nogueras Gonzalez G; Verstovsek S; Borthakur G; Wierda W; Kadia T; Dellasala S; Pierce S; Ravandi F; O'Brien S; Cortes J
Br J Haematol; 2016 Apr; 173(1):114-26. PubMed ID: 26846160
[TBL] [Abstract][Full Text] [Related]
14. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
15. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
17. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
18. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
Korkmaz S; Dal MS; Berber I; Sahin DG; Dogu MH; Ayyildiz O; Nizam I; Albayrak M; Esen R; Namdaroglu S; Sencan M; Akay OM; Hacioglu S; Yildirim R; Eser A; Tombak A; Pala C; Ilhan O
Geriatr Gerontol Int; 2015 Jun; 15(6):729-35. PubMed ID: 25257190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
